Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tocilizumab + hydroxychloroquine
- Development stage
- Preclinical
- Lead developer
- Chugai Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a **combination therapy** of tocilizumab, a recombinant humanized monoclonal antibody that antagonizes the interleukin-6 (IL-6) receptor, and hydroxychloroquine, a small molecule antimalarial with immunomodulatory properties. Tocilizumab inhibits IL-6-mediated signaling, blocking downstream pro-inflammatory pathways implicated in cytokine release syndromes, autoimmune arthritis, and COVID-19-related cytokine storm. Hydroxychloroquine modulates immune activity by interfering with lysosomal acidification, inhibiting Toll-like receptors (TLR7 and TLR9), reducing cytokine release, and affecting antigen presentation. This combination has been studied in severe COVID-19 with hyperinflammation, with clinical evidence suggesting potential efficacy in modulating cytokine storm parameters, but no clear mortality benefit has been established[1][3][7].
- Brand names
- Actemra + hydroxychloroquineRoActemra + hydroxychloroquineAvtozma + hydroxychloroquineTofidence + hydroxychloroquineTyenne + hydroxychloroquine
- Other names
- TCZ-HCQ
02
Targets
TLR9 (Toll-like receptor 9)IL-6R (Interleukin-6 receptor subunit alpha)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on tocilizumab + hydroxychloroquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tocilizumab + hydroxychloroquine.